This three day event will discuss aspects of Alzheimer's Disease development and treatment in an informal academic setting. This year there are three main topics for discussion.

1. Biomarker Discovery and Assay Development
2. Prevention Strategies and Vaccine Development
3. Drug Discovery and Development

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Alzheimer's Disease.

This event has CPD accreditation

www.regonline.co.uk/alz2014
Contents

Program Outline ........................................................................................................................................... 6

Day 1: Biomarker Discovery and Assay Development ................................................................................. 6
  Session Chair: Amos Korczyn ...................................................................................................................... 6

Day 2: Prevention Strategies and Vaccine Development .................................................................................. 6
  Session Chair: ........................................................................................................................................ 6

Day 3: Drug Discovery and Development ..................................................................................................... 6
  Morning Session Chair: Botond Penke ....................................................................................................... 6
  Afternoon Session Chair: .......................................................................................................................... 6

Agenda .......................................................................................................................................................... 7

Day 1: Biomarker Discovery and Assay Development .................................................................................. 7
  Introduction by the Chair ............................................................................................................................ 7
  Why have we failed to cure AD? .................................................................................................................. 7
  Alzheimer's disease in Down's syndrome - an ideal model for biomarker discovery? ......................... 7
  Is AD A Medical Notion of Dementia Worth Keeping in Neuroscience? .............................................. 7
  Oral Presentation ....................................................................................................................................... 7
  Oral Presentation ....................................................................................................................................... 7
  Amyloid hypothesis for AD: Insight from single molecule experiments and computational analyses, ... 7
  The biomarkers assessment in a Memory Clinic: is there any added value? ........................................ 7
  Cerebrospinal fluid Presenilin-1: a potential new biomarker for Alzheimer's disease ......................... 7
  Investigation of novel functional and metabolic MRI biomarkers for the preclinical assessment of tauopathy in AD ........................................................................................................................................ 7

Day 2: Prevention Strategies and Vaccine Development ............................................................................... 8
  Introduction by the Chair ............................................................................................................................ 8
  SemiAlloGeneic Vaccines for Alzheimer's Disease ..................................................................................... 8
  What did we learn from the first clinical trial of Aβ immunotherapy? ...................................................... 8
  Multiscale computational approach illuminating novel common pathways between diabetes and AD . 8
  Oral Presentations ....................................................................................................................................... 8
  Oral Presentations ....................................................................................................................................... 8
  Regulatory T cells as new targets for immunotherapy in Alzheimer's disease? .................................... 8
  Moving DNA immunization toward an Alzheimer's disease clinical trial ............................................. 8

Day 3: Drug Discovery and Development .................................................................................................... 9
  Introduction by the Chair ............................................................................................................................ 9
  Oral Presentation ....................................................................................................................................... 9
THE AGED BEAGLE MODEL OF ALZHEIMER’S DISEASE PROGRESSION.................................9
New era in AD drug design: intracellular and exosomal targets ........................................9
Oral Presentations .................................................................................................................9
Introduction by Chair ...........................................................................................................9
The enemies within: the role of herpes simplex virus type 1 (HSV1) and APOE-e4 in Alzheimer’s disease .........................................................................................................................9
Oral Presentation .................................................................................................................9
FUNCTIONAL INTERACTION BETWEEN PRION AND AB IN NEURONAL MEMBRANES. ..........................................................9
Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease ......................................................................................................................9
Oral Presentation .................................................................................................................9
LATE DANTROLENE TREATMENT REDUCED AMYLOID BURDEN IN ALZHEIMER TRIPLE TRANSGENIC MICE.................................................................................................9
Combining drug-like fragments in multitarget new chemical entities for Alzheimer’s disease............................................................9
How to Prevent Dementia and Alzheimer’s ........................................................................9
Activities of daily living: a new approach to discovering Alzheimer therapies .........................9
About the Speakers .............................................................................................................10
Day 1 ......................................................................................................................................10
Shahid Zaman .......................................................................................................................10
Adrian Ivanoiu ......................................................................................................................10
Yuri Lyubchenko, ...............................................................................................................10
Javier Sáez-Valero ...............................................................................................................10
Niall Colgan ........................................................................................................................11
Day 2 ......................................................................................................................................11
Mark Kindy ..........................................................................................................................11
Delphine Boche ....................................................................................................................11
Giulio Maria Pasinetti ..........................................................................................................11
David H. Cribbs, ..................................................................................................................11
Day 3 ......................................................................................................................................12
Hugo Geerts ........................................................................................................................12
Željko M. Svedružić .............................................................................................................12
Andrea Cavalli ......................................................................................................................12
Allen J. Orehek, MD ...........................................................................................................12
Robert Deacon ......................................................................................................................12
Discussion Sessions ..........................................................................................................13
Session breaks ....................................................................................................................13
Lunch........................................................................................................................................13
- All the chicken in our lunch buffet is Halal ..................................................................................13
- We have a number of dishes that are gluten free ..................................................................................13
- We have a range of vegetarian dishes which are separated from the meat and fish dishes.........13

Frequently asked questions about our events..................................................................................14
  Is the delegate list available? ..................................................................................................................14
  Can I have the speakers slides? ...............................................................................................................14
  Can I have a notepad? ...............................................................................................................................14
  How can I keep up to date with Euroscicon Events? ...........................................................................14
  I don't want my photograph on any Euroscicon promotional material ..........................................14
  Is there WIFI? ........................................................................................................................................14
  Can I have a CPD certificate? ....................................................................................................................14
Program Outline

Day 1: Biomarker Discovery and Assay Development
Currently, there are many biomarkers for diagnosis of Alzheimer’s disease. However most of them do not provide consistent results. This session will discuss current research aimed at obtaining reliable biomarkers which could be used to diagnose Alzheimer's disease at very early stage and also to provide objective and reliable measures of disease progress.

Session Chair: Amos Korczyn
Amos Korczyn: Graduated from the Hebrew University, Hadassah Medical School in Jerusalem MD and MSc in pharmacology (cum laude) in 1966. Trained in neurology at Beilinson Hospital and at the National Hospital, Queen Square, London. He was the Chairman of Neurology, Tel-Aviv Medical Center, 1981-2002, and incumbent of the Sieratzki Chair of Neurology at Tel-Aviv University, 1995-2010. Has a particular interest in neurodegenerative diseases, and authored or co-authored over 600 articles, as well as book chapters. Professor Korczyn is the Chairman of the Scientific Advisory Board of the Israeli Alzheimer's disease association (EMDA), and member of the SAB of Alzheimer Disease International.

Day 2: Prevention Strategies and Vaccine Development
This session will discuss current research into Alzheimer’s Disease prevention including vaccine development. There will be plenty of opportunity for discussion and debate.

Session Chair: Guillaume Dorothee
is a neuroimmunologist, Senior Investigator and group leader at the french National Institute of Health and Medical Research (INSERM), Paris, France. His main expertise relates to both innate and adaptive immunity in neurodegenerative diseases. He obtained his Ph.D in Immunology in 2003 from University Paris-VI, France, and trained as a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center, New York, and Curie Institute, Paris. His main research interests focus on understanding the role and therapeutic potential of adaptive immune responses in Alzheimer's disease, and developing immune-based biomarkers in AD.

Day 3: Drug Discovery and Development
There are currently no treatments that will stop or reverse the progress of Alzheimer's disease. With an aging population and increasing number of people with Alzheimer's, the need to develop ways to halt and treat the disease have become paramount. This session will discuss current research into Alzheimer's drug discovery and development including analysis of current clinical trials.

Morning Session Chair: Botond Penke

Afternoon Session Chair: Ruth Itzhaki,
her first degree was in physics, and subsequent MSc and PhD degrees were in Biophysics - all London University. She then moved to Cambridge, to the University Department of Radiotherapeutics, holding a Beit Memorial Fellowship for Medical Research and the Wheldale-Onslow Memorial Fellowship at Newnham College. On her next move, to Manchester, she worked initially in the Paterson Laboratories, subsequently in the Optometry and Neuroscience Department, UMIST and then in the University of Manchester. Her research topics have been diverse: iron-binding in plasma; effects of ionising radiation on natural and synthetic macromolecules; chromatin structure; effects of irradiation on chromatin; carcinogens and chromatin; and most recently, viruses and neurological disease.
## Agenda (Talk times include 5 – 10 minutes for questions)

<table>
<thead>
<tr>
<th>Day 1: Biomarker Discovery and Assay Development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>09:30 – 10:15</strong></td>
</tr>
<tr>
<td><strong>10:15 – 11:00</strong></td>
</tr>
<tr>
<td><strong>11:00 – 11:30</strong></td>
</tr>
<tr>
<td><strong>11:30 – 12:00</strong></td>
</tr>
<tr>
<td><strong>12:00 – 12:30</strong></td>
</tr>
<tr>
<td><strong>12:30 – 13:00</strong></td>
</tr>
<tr>
<td><strong>12:30 – 12:45</strong></td>
</tr>
<tr>
<td><strong>12:45 – 13:00</strong></td>
</tr>
<tr>
<td><strong>13:00 – 14:00</strong></td>
</tr>
<tr>
<td><strong>14:00 – 14:15</strong></td>
</tr>
<tr>
<td><strong>14:15 – 14:45</strong></td>
</tr>
<tr>
<td><strong>14:45 – 15:15</strong></td>
</tr>
<tr>
<td><strong>15:15 – 15:45</strong></td>
</tr>
<tr>
<td><strong>15:45 – 16:15</strong></td>
</tr>
<tr>
<td><strong>16:15 – 16:45</strong></td>
</tr>
<tr>
<td><strong>16:45 – 17:00</strong></td>
</tr>
<tr>
<td>Time</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>09:30 – 10:15</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
</tr>
<tr>
<td>11:30 – 12:00</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
</tr>
<tr>
<td>12:30 – 13:00</td>
</tr>
<tr>
<td>12:30 – 12:45</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
</tr>
<tr>
<td>13:00 – 13:45</td>
</tr>
<tr>
<td>13:45 – 14:15</td>
</tr>
<tr>
<td>14:15 – 15:00</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
</tr>
<tr>
<td>16:30</td>
</tr>
<tr>
<td>Time</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>09:30 – 10:15</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
</tr>
<tr>
<td>11:00 – 11:10</td>
</tr>
<tr>
<td>11:10 – 11:40</td>
</tr>
<tr>
<td>12:00 - 12:20</td>
</tr>
<tr>
<td>13:45 – 14:15</td>
</tr>
<tr>
<td>14:15 – 14:25</td>
</tr>
<tr>
<td>14:25 – 14:55</td>
</tr>
<tr>
<td>14:45 – 15:20</td>
</tr>
<tr>
<td>15:20 – 15:30</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
</tr>
<tr>
<td>17:00</td>
</tr>
</tbody>
</table>
About the Speakers

Day 1

Shahid Zaman is a consultant neuropsychiatrist and neuroscientist in the Department of Psychiatry at the University of Cambridge. He has researched in the field of dementia in Down's syndrome for several years. He obtained his medical degree from the University of Sheffield and undertook a PhD in molecular neurobiology at Cambridge which was followed by an award of a Welcome Trust Fellowship to study hippocampal synaptic plasticity of autosomal dominant presenilin-1 mutations at Cold Spring Harbor, USA.

Fred C. C. Peng is a neuroscientist in the Neurological Institute at Taipei Veterans General Hospital, Taiwan. He is listed in Who's Who in the World by Marquis. He has published two books: (1) Does Alzheimer's Disease Really Exist? and (2) Alzheimer's Disease: What Is It After All? His purpose is to set the misleading historical record straight so as to recognize Oskar Fischer for the overdue credit of Fischer's Disease (FD) he deserved in 1907-1910, a rightful eponym in place of AD, for the benefits of millions of people with dementia who have been misdiagnosed to have AD.

Adrian Ivanoiu is a clinical neurologist and neuroscientist. He defended a doctoral thesis on cognitive and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment and Alzheimer disease. He collaborated with Professor John Hodges at MRC Cognition and Brain Sciences Unit, Cambridge, UK. He is in charge of the Memory Clinic of Saint Luc University Hospital and leads a research group at the Institute of Neuroscience of the Catholic University of Louvain, Brussels, Belgium. Professor Ivanoiu is interested in the evaluation of cognitive and biological markers of neurodegeneration: episodic memory, CSF, MRI, PET scan.

Yuri Lyubchenko, is Professor at the Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE (USA). He graduated from Moscow Institute Physics and Technology (MIPT, Russia) with the MS degree in Physical Chemistry. He holds PhD degree in Molecular Biophysics (1971, MIPT, Russia) and DSc degree in Molecular biology (1989, Institute of Molecular Genetics, Moscow, Russia). His research is focused in three areas: (1) molecular mechanisms of HIV restriction by cytosine deaminases, (2) DNA structure and dynamics in relation to DNA recombination and replication and (3) molecular mechanisms of Alzheimer’s, Parkinson’s and similar neurodegenerative diseases.

Javier Sáez-Valero is a Lecturer in Biochemistry and Molecular Biology at the Miguel Hernández University of Spain, leading a group at the Instituto de Neurociencias, the first Spanish research institute devoted to the better knowledge of the nervous system in health and disease. His group is also member of The Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), a “networked” institute that represent the Spanish initiative to combat neurodegenerative diseases, bringing together the best basic and clinical neuroscience research groups. Sáez-Valero aims to introduce a line of research into Alzheimer’s disease (AD) and dementia that originated from a basic point of view but relevant to the development of clinical-diagnostic applications.

Abhay Moghekar is an Asst Prof of Neurology who studies the role of CSF biomarkers in aging. He is an investigator in 2 NIH funded studies - the Baltimore Longitudinal Study of Aging and the Biomarkers for Older Controls at Risk for Dementia.
Niall Colgan is a Senior Research Associate in the Centre for Advanced Biological Imaging in the College of Medicine at University College London. His research is in the area of preclinical biomarkers in Alzheimer's disease and drug discovery and his specialty area is Magnetic resonance imaging, metabolism and experimental therapeutics. Prior to this he was a lecturer in Medical Imaging (MRI) in the College of Medicine at Swansea University and worked in Trinity College Dublin in MRI related to traumatic brain injury, University College Dublin in neurological MRI. His primary research focus is magnetic resonance imaging, particularly MR metabolite imaging and diffusion MRI.

Day 2

Mark Kindy is a neuroscientist and Professor in the Department of Neurosciences at the Medical University of South Carolina and a Senior Research Career Scientist at the Ralph H. Johnson VA Medical Center in Charleston, SC. He received his BS from the University of Massachusetts in Zoology and PhD from Boston University School of Medicine in Biochemistry. He was a postdoctoral fellow at the Salk Institute. He started his faculty career at the University of Kentucky, School of Medicine in the Department of Biochemistry and the Center on Aging. His area of expertise is neurodegenerative disorders.

Delphine Boche is a Senior Lecturer in Clinical Neurosciences at the University of Southampton, UK. Her main research is to understand the role of neuroinflammation in relation with the neuropathology in neurological diseases and has now developed an expertise in clinical neuroimmunopathology. She obtained her PhD in 1997 from the University Paris-VI where she investigated the pathophysiology of the HIV-dementia using animal models. Then, she moved to Southampton to study the neuroinflammation in neurodegenerative diseases using mouse models before joining the Faculty of Medicine to explore the pathophysiology of Alzheimer’s disease following the active Aβ42 immunotherapy.

Giulio Maria Pasinetti is the Chief of the Brain Institute Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics and is a professor of Neurology, Psychiatry, Neuroscience, Geriatrics and Adult Development at the Icahn School of Medicine at Mount Sinai. Pasinetti also serves as the Director of the Basic and Biomedical Research and Training, Geriatric Education and Clinical at the Bronx Veterans Affairs Medical Center. Dr. Pasinetti’s research on lifestyle factors and metabolic co-morbidities, including diabetes, influencing clinical dementia, neurodegeneration and Alzheimer’s disease has made him one of the top experts in his field. Dr. Pasinetti is the recipient of several academic awards, including the prestigious Zenith and Temple awards from the Alzheimer’s Association, the Nathan W. and Margaret T. Shock Aging Research Foundation Award of the Gerontological Society of America, and the Foundation Queen Sofia of Spain Research Center Award on Alzheimer’s Disease. Most recently, Dr. Pasinetti received The Faculty Council Award for academic excellence at Mount Sinai School of Medicine and The Charles Dana Alliance for Brain Research Award from the Dana Foundation, recognizing productivity and worldwide leadership in his field of expertise. Dr. Pasinetti is the recipient of more than 30 grants and has published over 300 groundbreaking manuscripts.

David H. Cribbs, Professor and Associate Director, Institute for Memory Impairment and Neurological Disorders, University of California, Irvine, USA

He received a B.S. from St. Mary’s College of Maryland, and a PhD in Biochemistry from West Virginia University. He was awarded a National Institutes of Health (NIH) Postdoctoral Fellowship while at the Department of Biophysics, Johns Hopkins University. Dr. Cribbs has published more than 120 research articles in peer-reviewed journals, has served on numerous NIH Study Sections, and is a member multiple scientific societies. In 2008 he received the Van den Noort Award for Outstanding Research in Neuroscience.
Day 3

Hugo Geerts is currently Chief Scientific Officer of In Silico Biosciences, a company providing mechanistic disease modeling services in CNS R&D. His education includes theoretical quantum-mechanics and a PhD in Biophysics, a Bachelor Degree in Medicine and a Master in Pharmaceutical Sciences. He worked for 17 years with Dr. Paul Janssen, the greatest drug hunter in history at the Janssen Research Foundation (J&J) leading the Alzheimer Discovery research with programs in tangle and b-amyloid pathology and supported the successful clinical development of galantamine. He is faculty of the Upenn Perelman School of Medicine and the Drexel University Pharmacology Department.

Željko M. Svedružić is currently Assistant professor at Department of Biotechnology and at Faculty of Medicine, University of Rijeka, Croatia. Dr Svedružić got his training in γ-secretase and the related drug-development efforts, working as a senior scientist on a collaborative project between world leading expert Professor Bart de Strooper and Drug Hunting Team of Eli Lilly Company. Dr Svedružić earned his Ph.D. in enzymology from Oklahoma State University, and did his postdoctoral research at University of California at Santa Barbara, Duke University, and Washington State University.

Andrea Cavalli is Associate Professor of Medicinal Chemistry at the University of Bologna and Head of Computational Chemistry and Structural Biophysics at the Italian Institute of Tecnology, Genova. Prof. Cavalli received his PhD in Pharmaceutical Sciences from the University of Bologna in 1999 and did postdoctoral work at SISSA (Trieste, Italy) and ETH (Zurich, Switzerland). He is an author of more than 140 scientific articles published in high-ranked journals and inventor in 8 international patents. He has delivered more than 50 invited lectures and seminars at international congresses and prestigious institutions. He is member of the Editorial Board of several international journals, and since 2012 he is an Academic Editor of PLoS ONE. He is also a member of the Scientific Council of CINECA, the largest Italian Supercomputing Center. Prof. Cavalli’s research has combined computational chemistry to drug discovery, focusing on neurodegenerative diseases, cancer, and neglected tropical diseases. In 2003, he was awarded the Farmindustria Prize for Pharmaceutical Research.

Allen J. Orehek, MD is an innovator and physician whose unique talent is the prevention of dementia and Alzheimer's. Board certified in Internal Medicine and Pediatrics, Orehek's fresh new concepts are designed for the motivated individual. It is a method that has resulted in stopping progression of dementia for many and providing reversal for some. Works include: 'The Micron Stoke Hypothesis of Alzheimer's Disease and Dementia' (Medical Hypotheses 78 (2012) 562-570).Prevention is Difficult - But Possible on amazon.com.

Robert Deacon obtained his first degree in pharmacology at the University of Wales, where he also studied psychopharmacology for his doctorate. After learning stereotaxic surgery at Bradford University, he spent 8 years in the pharmaceutical industry (Roussel Laboratories) before starting research at Oxford University in 1991. He has worked extensively on the hippocampus and its function in mice and rats, and about 10 years ago formulated the novel idea that the hippocampus was vital for mediating species-typical behaviours, equivalent to rodent ADL, and proposed that these ADL tests could be used to provide an alternative approach in the hunt for new AD therapies.
Discussion Sessions

The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speaker's session, but for discussing either general topics or specific issues.

Session breaks

All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you.

Lunch

- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes
Frequently asked questions about our events

Is the delegate list available?
Yes this is available to everyone who attends the event and our sponsors. It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event. You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?
We cannot give out the slides from our speaker’s presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?
Notepads and pens are provided in the delegate bags and at the registration desk.

How can I keep up to date with Euroscicon Events?
To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com.

I don’t want my photograph on any Euroscicon promotional material
Please let our tech person know.

Is there WIFI?
Yes, please ask registration for log in details.

Can I have a CPD certificate?
CPD certificates will be available in the exhibition hall after lunch.

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations.